Lupin unveils generic version of Sun Pharma Westcort Cream to treat skin conditions

Published On 2019-11-23 07:44 GMT   |   Update On 2019-11-23 07:44 GMT

Hydrocortisone Valerate Cream USP, 0.2%, is the generic equivalent of the Westcort Cream, 0.2%, of Sun Pharmaceutical Industries Inc., Lupin said.


New Delhi: Pharma major Lupin Limited (Lupin) recently announced the launch of Hydrocortisone Valerate Cream USP, 0,2%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.


Lupin's Hydrocortisone Valerate Cream USP, 0.2%, is the generic equivalent of the Westcort Cream, 0.2%, of Sun Pharmaceutical Industries Inc.


It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adult patients.


Also Read: Lupin to sell Japanese arm Kyowa Pharma to Unison for Rs 3702 crore


Hydrocortisone Valerate Cream USP, 0.2%, (RLD: Westcort Cream) had an annual sales of approximately USD 11.5 million in the U.S. (IQVIA MAT September 2019).


Headquartered in Mumbai, Lupin develops and delivers a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds a global position in the Anti-TB segment.


Also Read: Lupin gets USFDA nod for a generic equivalent of Zyflo CR Extended-Release Tablets to treat prophylaxis, asthma

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News